Maro Ohanian

6.4k citations

120 papers · 1.8k indexed · h-index 24

Impact in

Hematology top 0.5%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
Genetics top 2%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

Hematology 99
- Acute Myeloid Leukemia Research 78
- Chronic Myeloid Leukemia Treatments 41
Genetics 56
- Chronic Lymphocytic Leukemia Research 31
- Myeloproliferative Neoplasms: Diagnosis and Treatment 21

Co-authors: Hagop M. Kantarjian Jörge E. Cortes Farhad Ravandi Elias Jabbour Tapan M. Kadia Gautam Borthakur Guillermo Garcia‐Manero Naval Daver
Journals: Blood (57 papers)Journal of Clinical Oncology (15 papers)American Journal of Hematology (10 papers)Leukemia Research (3 papers)Cancer (2 papers)
Partner nations: United States Georgia Armenia

In The Last Decade

Maro Ohanian

114 papers receiving 1.7k citations

Peers

Countries citing papers authored by Maro Ohanian

Since Specialization

Citations

This map shows the geographic impact of Maro Ohanian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maro Ohanian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maro Ohanian more than expected).

Fields of papers citing papers by Maro Ohanian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maro Ohanian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maro Ohanian. The network helps show where Maro Ohanian may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Maro Ohanian, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Maro Ohanian Line = papers co-authored together Maro Ohanian links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis Blood ·Kechu Huang, Hagop Kantarjian, Koji Sasaki, Nitin B. Jain, Caitlin R. Rausch, Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Naveen Pemmaraju, Farhad Ravandi, Guillermo Montalban‐Bravo, Guillermo Garcia‐Manero, Danielle Hammond, Mahesh Swaminathan, Diane M. Flynn, Maro Ohanian, Rebecca Garris, Nicholas J. Short, Elias Jabbour	2025	0
2	Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome Leukemia Research ·Adrien Kopp, Guillermo Montalban‐Bravo, Farhad Ravandi, Nicholas J. Short, Rahmi Yuningsih, Maro Ohanian, Kelly S. Chien, Lucia Masárová, Koji Sasaki, Musa Yılmaz, Florian Belavić, Naval Daver, Gautam Borthakur, Elias Jabbour, Heather Schneider, L. Michael Romero, H. Kantarjian, Guillermo Garcia‐Manero	2025	1
3	Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up Blood ·Jayastu Senapati, H. Kantarjian, Edward Ayoub, Suhail S. Alhejji, Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Fadi Haddad, Naveen Pemmaraju, Nicholas J. Short, Maro Ohanian, Musa Yılmaz, Keyur P. Patel, 江光华, Sherry Pierce, Guillermo Garcia‐Manero, Farhad Ravandi, Gautam Borthakur	2024	1
4	Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results Blood ·Deodatus Tummers, Gautam Borthakur, Koji Sasaki, Guilin Tang, Guillermo Montalban‐Bravo, Elias Jabbour, Maro Ohanian, Musa Yılmaz, Fadi Haddad, Kelly S. Chien, Jo Ishizawa, Nicholas J. Short, Abhishek Maiti, Mahesh Swaminathan, Guillermo Garcia‐Manero, Naval Daver, Courtney D. DiNardo, Farhad Ravandi, Tapan M. Kadia	2023	0
5	Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study Blood ·Alexandre Bazinet, Hagop M. Kantarjian, Farhad Ravandi, Nicholas J. Short, Naval Daver, Maro Ohanian, Musa Yılmaz, Kelly S. Chien, Abhishek Maiti, Courtney D. DiNardo, Jo Ishizawa, Lucia Masárová, Luana De Paula dos Santos da Silva, Gautam Borthakur, Elias Jabbour, Guillermo Garcia‐Manero, Tapan M. Kadia	2023	2
6	Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia American Journal of Hematology ·Jayastu Senapati, Mahran Shoukier, Guillermo Garcia‐Manero, Xuemei Wang, Keyur P. Patel, Tapan M. Kadia, Farhad Ravandi, Naveen Pemmaraju, Maro Ohanian, Naval Daver, Courtney D. DiNardo, Yesid Alvarado, K. Bork, Gautam Borthakur	2022	15
7	Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients American Journal of Hematology ·Gautam Borthakur, Farhad Ravandi, Keyur P. Patel, Xuemei Wang, Tapan M. Kadia, Courtney D. DiNardo, Guillermo Garcia‐Manero, Naveen Pemmaraju, Elias Jabbour, Koichi Takahashi, Maro Ohanian, Naval Daver, Yesid Alvarado, Mark Brandt, Sherry Pierce, Hagop M. Kantarjian	2022	20
8	Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10⁻⁴ and higher American Journal of Hematology ·Elias Jabbour, Nicholas J. Short, Nitin Jain, Fanny Ramadhani, Jeffrey L. Jorgensen, Sa Wang, Xuemei Wang, Maro Ohanian, Yesid Alvarado, Tapan M. Kadia, Koji Sasaki, Rebecca Garris, Guillermo Garcia‐Manero, Farhad Ravandi, Hagop M. Kantarjian	2022	23
9	Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy Blood Cancer Journal ·Sangeetha Venugopal, Koichi Takahashi, Naval Daver, Abhishek Maiti, Gautam Borthakur, Sanam Loghavi, Nicholas J. Short, Maro Ohanian, Lucia Masárová, Ghayas C. Issa, Xuemei Wang, Blessing Johnson Ukpong, Musa Yılmaz, Tapan M. Kadia, Michael Andreeff, Farhad Ravandi, Marina Konopleva, Hagop M. Kantarjian, Courtney D. DiNardo	2022	63
10	Freeze‐dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies American Journal of Hematology ·Maro Ohanian, José A. Cancelas, Robertson D. Davenport, Vinod Pullarkat, Tor Hervig, Catherine M. Broome, Luz Holanda Viana Ricardo, Mary Ann Kelly, Viviana Durán, Neeta Rugg, P Ralph, Satish Kavatagimath, Zbigniew M. Szczepiorkowski, Hagop M. Kantarjian, Joan C. Pehta, N. Van Acker, Anna Yu, Fleur M. Aung, Ben Antebi, هاني فوزي أبو العزم	2021	13
11	Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2 Blood ·Christopher P. Mill, Warren Fiskus, Courtney D. DiNardo, Christine Birdwell, John A. Davis, Tapan M. Kadia, Koichi Takahashi, Nicholas J. Short, Naval Daver, Maro Ohanian, Gautam Borthakur, Steven M. Kornblau, Michael R. Green, Yuan Qi, Xiaoping Su, Joseph D. Khoury, Kapil N. Bhalla	2021	48
12	Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax Cancer ·Kunhwa Kim, Abhishek Maiti, Sanam Loghavi, Rasoul Pourebrahim, Tapan M. Kadia, Caitlin R. Rausch, Ken Furudate, Naval Daver, Yesid Alvarado, Maro Ohanian, Koji Sasaki, Nicholas J. Short, Koichi Takahashi, Musa Yılmaz, Guilin Tang, Farhad Ravandi, Hagop M. Kantarjian, Courtney D. DiNardo, Marina Konopleva	2021	100
13	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia American Journal of Hematology ·Yasmin Abaza, Hagop M. Kantarjian, Giulia Griggio, Gautam Borthakur, Richard E. Champlin, Tapan M. Kadia, Guillermo Garcia‐Manero, Naval Daver, Farhad Ravandi, Srđan Verstovšek, Jan A. Burger, Zeev Estrov, Maro Ohanian, 王社芬, Naveen Pemmaraju, Elias Jabbour, Jörge E. Cortes	2020	31
14	Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia Clinical Lymphoma Myeloma & Leukemia ·Abhishek Maiti, Kiran Naqvi, Tapan M. Kadia, Gautam Borthakur, Koichi Takahashi, Prithviraj Bose, Naval Daver, Ami Patel, Yesid Alvarado, Maro Ohanian, Courtney D. DiNardo, Jörge E. Cortes, Elias Jabbour, Guillermo Garcia‐Manero, Hagop M. Kantarjian, Farhad Ravandi	2018	36
15	Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients Blood ·Shyamala Navada, Guillermo Garcia‐Manero, Ehab Atallah, Flávia Moura Malani Drummond, Jamile M. Shammo, Elizabeth A. Griffiths, Samer K. Khaled, Shaker R. Dakhil, David Young, Rosalie Odchimar-Reissig, Naveen Pemmaraju, Yesid Alvarado, Maro Ohanian, Bruno Fonte, Becca Blubaugh, Manoj Maniar, Michael E. Petrone, Steven Fruchtman, Lewis R. Silverman	2018	10
16	Results of Off-Label Venetoclax Use in Combination with Low-Intensity Chemotherapy in Patients with Relapsed and Refractory Myeloid Malignancies Blood ·Caitlin R. Rausch, Courtney D. DiNardo, Tapan M. Kadia, Koichi Takahashi, Nitin Jain, Christopher B. Benton, Philip A. Thompson, Maro Ohanian, Wendy Covert, Morgan Mace, Kayleigh Marx, Naveen Pemmaraju, Naval Daver, Elias Jabbour, Jörge E. Cortes, Guillermo Garcia‐Manero, Farhad Ravandi, Marina Konopleva, Hagop M. Kantarjian	2017	3
17	Efficacy and Safety of Generic Imatinib after Switching from Innovator Imatinib in Patients Treated for Chronic Myeloid Leukemia Blood ·Ting Deng, Hagop M. Kantarjian, Jan A. Burger, Zeev Estrov, Maro Ohanian, Elias Jabbour, Srđan Verstovšek, Farhad Ravandi, Gautam Borthakur, Guillermo Garcia‐Manero, Jörge E. Cortes	2017	1
18	Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL) Blood ·Jan A. Burger, Mariela Sivina, Alessandra Ferrajoli, Nitin Jain, Ekaterina Kim, Tapan M. Kadia, Zeev Estrov, Graciela Nogueras González, Xuelin Huang, Maro Ohanian, Michael Andreeff, Mathew Thomas, Kazumasa Horie, Hagop M. Kantarjian, Susan O’Brien, William G. Wierda, Michael J. Keating	2017	11
19	Portal Vein Thrombosis After Laparoscopic Cholecystectomy JSLS Journal of the Society of Laparoscopic & Robotic Surgeons ·Naruhiko Ikoma, T. Oliveira Pires, Maro Ohanian, Harinder S. Juneja, Bruce V. MacFadyen, Shinil K. Shah, Kulvinder S. Bajwa	2014	9
20	Isolated Mesenteric CD20-Positive Myeloid Sarcoma Clinical Lymphoma Myeloma & Leukemia ·Maro Ohanian, Richard S.P. Huang, V. V. Gladilov, Zeev Estrov, Harinder S. Juneja, Lei Chen, Modupe Idowu, Lynne V. Abruzzo	2014	10

About Maro Ohanian

Maro Ohanian is a scholar working on Hematology, Genetics, Public Health, Environmental and Occupational Health, Oncology and Molecular Biology, having authored 120 papers that have together received 1.8k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (78 papers), Chronic Myeloid Leukemia Treatments (41 papers), Chronic Lymphocytic Leukemia Research (31 papers), Acute Lymphoblastic Leukemia research (22 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (21 papers), Histone Deacetylase Inhibitors Research (19 papers), Protein Degradation and Inhibitors (11 papers) and Lymphoma Diagnosis and Treatment (8 papers). The work is most often cited by research in Hematology (1.2k citations), Genetics (528 citations), Public Health, Environmental and Occupational Health (346 citations), Oncology (306 citations) and Immunology (220 citations). Maro Ohanian has collaborated with scholars based in United States, Georgia and Armenia. Frequent co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Farhad Ravandi, Elias Jabbour, Tapan M. Kadia, Gautam Borthakur, Guillermo Garcia‐Manero, Naval Daver, Marina Konopleva and Naveen Pemmaraju. Their work appears in journals such as Blood, Journal of Clinical Oncology, American Journal of Hematology, Leukemia Research and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact